Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 12, 2007

BioWa and Lonza Will Pool Tools to Develop Enhanced Antibody Platform

  • BioWa and Lonza agreed to bring together their technologies to create a new antibody platform. BioWa’s Potelligent® and Lonza’s GS Gene Expression System™ and CHOK1SV cell line will be combined.

    The companies expects to generate a new platform that will produce more potent antibodies with greatly enhanced antibody-dependent cellular cytotoxicity (ADCC) in a high-yield mammalian expression system for industry-wide use.

    Under the terms of the agreement, the new Potelligent CHOK1SV cell line will be available for licensing as part of Lonza’s development services in combination with the firm’s GS Gene Expression System. The two companies will jointly market the new technology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »